Waldenström macroglobulinemia (shortened to WM) is a rare blood cancer. WM usually progresses slowly; some people do not show symptoms for several years after diagnosis. A person who does not have symptoms usually does not need treatment, but active monitoring is essential so that treatment can be started as soon as it is needed. Although there is no cure for WM, different treatment options can keep the disease under control for many years in a lot of people. Eventually, the treatments tend to lose their effect. New therapies are being tested in clinical trials across the world, with promising results. Table of Contents: • What is Waldenström macroglobulinemia? How will WM affect me? Who is in my care team? What tests will I need to have? Common feelings when diagnosed • Helping yourself • Active monitoring • Starting treatment • Types of treatment • What are supportive treatments? How do I know if treatment has worked? Follow-up after treatment • When WM comes back • Research and new treatments • Understanding WM

Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by the presence of an immunoglobulin M (IgM) monoclonal protein. WM is a chronic, indolent disease, which can remain undiagnosed for years. A better understanding of the role of signaling pathways in the development of the disease and the identification of clinical and genetic markers have driven the development of targeted therapeutic strategies, improving overall survival.

For nearly 25 years, Ferri's concise, pocket-sized resource has served as the go-to reference for practical, clinical information among students, residents, and other medical professionals. Formerly known as Practical Guide to the Care of the Medical Patient, this volume continues to provide a fast, effective, and efficient way to identify the important clinical, laboratory, and diagnostic imaging information you need to get through your internal medicine clerkship or residency. - Consult this title on your favorite device, conduct rapid searches, and adjust font sizes for optimal readability. - Benefit from the expert guidance of Dr. Fred Ferri, a leading teacher, clinician, and author. - Confidently manage patients with the latest clinical information, drug therapies, and lab tests. - Apply the latest knowledge and techniques with this updated and streamlined title, which still stays true to the Ferri name. - Quickly find important information with content organized into three major sections: Section I, titled "Surviving the Wards," contains information on charting, laboratory evaluation and formulary; Section II provides the differential diagnosis of common signs and symptoms likely to be encountered in the acute care setting; Section III has been completely revised and subdivided into 11 specialty specific diseases and disorders. - Carry just the sections you need, add personalized materials, and keep everything together and safe with an improved ring binder and design. - Access the full text and procedural videos online at Expert Consult.

'Fast Facts: Marginal Zone Lymphoma' provides an overview of MZL for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, staging, and prognosis, together with existing approaches to treatment and monitoring, including the latest evidence for new therapies in the R/R setting. With an eye to the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with MZL.

Hodgkin lymphoma and the many different subtypes of non-Hodgkin lymphoma (NHL) have different responses to treatment, so accurate diagnosis and a rational approach to management are essential. 'Fast Facts: Lymphoma' distills the most important aspects of the diagnosis and management of these complex disorders into a highly accessible well-illustrated summary of the key facts. This fully updated second edition provides: • a clear outline of the nature of lymphoma • the essentials of clinical presentation, biopsy and basic histology • the latest laboratory diagnostics, including immunophenotyping, cytogenetics and microarray technology • key aspects of staging and initial therapy • superbly illustrated overviews of the pathology, presentation, treatment and prognosis of each lymphoma subtype • new treatment options, including targeted biological therapies • a practical overview of supportive care for the complications of lymphoma Written by three experts in the field from the UK and USA, 'Fast Facts: Lymphoma' applies an international perspective to this challenging disease in a unique format within the context of clinical practice. It is a valuable resource for trainee doctors and specialist nurses working in the field of hemato-oncology. It will also be of interest to the inquiring patient or carer who wishes to know more about lymphoma. Contents: • Epidemiology • Cellular and molecular aspects • Presentation, biopsy and diagnostic laboratory techniques • Staging and general management principles • Aggressive B-cell lymphomas • Indolent B-cell lymphomas • T-cell and natural-killer cell lymphomas • Immunocompromised and HIV-positive patients • Hodgkin lymphoma • Treatment modalities • Supportive care

Most hemorrhagic problems are emergencies, requiring rapid diagnosis and prompt management to stop bleeding. In some cases, such as nose bleeds, large bruises and heavy menses, it is the clinician’s responsibility to discern whether the patient has a clinically significant bleeding disorder that may predispose to excessive or potentially serious bleeding. 'Fast Facts: Bleeding Disorders' keeps a complex subject simple and clinically oriented. The authors have made numerous updates to this second edition to ensure it provides essential information in a readily accessible format. Highlights include: • An expert overview of normal hemostasis • A clear assessment pathway, from taking an accurate history and focused clinical examination, to essential laboratory investigations • Objective criteria for diagnosing hereditary hemorrhagic telangiectasia • The latest guidelines on diagnosing and treating primary immune thrombocytopenia • A discussion of the benefits of prophylaxis in patients with hemophilia • Updated methods for evaluating and treating bleeding disorders in pregnancy • An overview of the scoring system for disseminated intravascular coagulation • Information on the latest anticoagulants and antithrombotics, including bleeding risks and strategies to control bleeding. 'Fast Facts: Bleeding Disorders' remains a comprehensive up-to-date reference that reflects the latest research and clinical guidelines. It will assist primary care providers, physician assistants, nurse-clinicians, pharmacists, residents and doctors in training as they confront the challenges of controlling bleeding in patients with hemophilia, von Willebrand disease, platelet disorders and thrombosis, or as a result of antithrombotic or anticoagulant therapy. It is a small book packed with important information, designed to swiftly improve patient treatment and outcomes. Contents: • Normal hemostasis • Assessment of bleeding symptoms • Vascular purpuras • Platelet disorders • Pharmacological hemostatic products • Hemophilia • von Willebrand disease • Uncommon congenital coagulation disorders • Liver and kidney disorders • Pregnancy • Perioperative bleeding • Disseminated intravascular coagulation • Anticoagulants and antithrombotic agents • Useful resources

Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies. This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes: - the new IMWG SLiM CRAB criteria - the latest advances in diagnostic tests and imaging - cytogenetics and genetic profiling - induction therapy prior to SCT - new lenalidomide- and bortezomib-based regimens - second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments. This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice. Contents: • Epidemiology and etiology Predisposing conditions associated with MM • Pathophysiology of MM and MGUS • Diagnosis, staging and monitoring of multiple myeloma • Genetics and multiple myeloma • Treatment of newly diagnosed multiple myeloma • Stem cell transplantation in multiple myeloma • Relapsed and refractory multiple myeloma • Bone disease and renal complications • AL amyloidosis • Rare plasma cell dyscrasias • Supportive care

This Handbook serves as a convenient, state-of-the-art and comprehensive resource on the pathogenesis, diagnosis, and treatment of glomerular diseases. Clinical approaches, modalities and challenges are provided, along with new developments since the publication of Kidney Disease Improving Global Outcomes (KDIGO): Glomerulonephritis. Chapters dedicated to glomerular diseases mirror the current classification schemes used by Nephrologists and Pathologists and will include definition and natural history, epidemiology, clinical manifestations, pathology, diagnosis, differential diagnosis, treatment (algorithms when appropriate), prognosis and future prospects and current direction of research. Contributing authors consist of internationally renowned glomerulonephritis experts, renal pathologists and clinical nephrologists who are engaged in the management of glomerular diseases in clinical pediatric and internal medicine practices. Glomerulonephritis fills a considerable knowledge gap for general nephrologists, providers involved with the care of patients with glomerular diseases, and researchers. It should also be of value to medical students, interns, residents and fellows, as well as all clinicians engaged in medical education.

Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.